Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin + Capecitabine in Advanced Solid Tumors
NCT02210364Phase 1Completed
- Sponsor
- PharmaMar
- Start
- Apr 2013
- Primary completion
- Oct 2016
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of lurbinectedin in breast cancer, pancreatic cancer (PC) and colorectal cancer (CRC), sponsored by PharmaMar. Primary endpoint: Recommended Dose of PM01183 in combination with capecitabine at 30 months. Started Apr 2013; status: completed.
02
Drugs
lurbinectedin
03
Conditions
breast cancerpancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02210364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210364.